MANNITOL Inf.-Lsg. 15, 10X250 ml

Mannitol infusion solution 15

Supin.: 1 L Cont.: Active ingredient: Mannitol 150 g. Otherwise. Exist.: Water for injections, sodium hydroxide solution 33 %.

REST: Therapy and prophylaxis of acute kidney failure as a result of trauma or shock after previous trial infusion, brain pressure lowering with intact blood-brain barrier, osmotherapy for brain edema prophylaxis and therapy, glaucoma, introduction of osmotic diories in oliguria/anuria, diagnosis of oliguria/anuria.

Against: Sustainable oliguria/anuria after trial infusion, cardiac decompensation, dehydration states, pulmonary edema, intracranial bleeding, hyperhydration, disruption of the blood-brain barrier, increased serumosmolarity, drain disruptions of the lower derivative urinary tract. An application during pregnancy and breastfeeding should only be used after strict use/risk assessment. Next: Especially in the event of overdosing and depending on the clinical state of the patient, undesirable shifts can occur in the electrolyte and water balance, which may be. in an increase in serum molarity, extracellular fluid surplus, reduction in the HB and hematocrit value, reducing the serum electrolytes and exit potassium from the cell into the extracellular space. Hand -sensitivity reactions up to shock states, water balance with dehydration, disorders in the electrolyte balance with electrolyte loss, headache, cramps, acute volume load of the cardio -circular system (after too quick infusion and the application of larger quantities and especially with insufficient urine output), tachycardia, formation of lung edema Restricted kidney function, nausea with vomiting, upper abdominal complaints, confusion.